(Nasdaq: IDRA) today shared positive interim results from Amsterdam UMC, Vrije Universiteit Amsterdam, the Netherlands, regarding its investigator-sponsored trial, INTRIM 1, involving tilsotolimod, Ideras synthetic Toll-like receptor 9 agonist. Based on these results, the trial has been stopped early.
XTON, Pa., May 17, 2022 (GLOBE NEWSWIRE) — Idera Pharmaceuticals, Inc. (Idera, we, and our) (Nasdaq: IDRA) today shared positive interim results from Amsterdam UMC, Vrije Universiteit Amsterdam, the Netherlands, regarding its investigator-sponsored trial, INTRIM 1, involving tilsotolimod, Ideras synthetic Toll-like receptor 9 agonist. Based on these results, the trial has been stopped early.